Who are Xarelto's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Apixaban 2.5 milligram, Apixaban single dose, rivaroxaban (10mg), Oroxid®, Rivaroxaban or Marcumar, Rivaroxaban Oral Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rivaroxaban.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Xarelto — Competitive Intelligence Brief

Xarelto (rivaroxaban) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct Factor Xa Inhibitor. Area: Oncology.

marketed Direct Factor Xa Inhibitor Factor Xa (FXa) Oncology Live · refreshed every 30 min

Target snapshot

Xarelto (rivaroxaban) — Johnson & Johnson. Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Xarelto TARGET	rivaroxaban	Johnson & Johnson	marketed	Direct Factor Xa Inhibitor	Factor Xa (FXa)	2011-01-01
Apixaban 2.5 milligram	Apixaban 2.5 milligram	McMaster University	marketed	Direct Factor Xa inhibitor	Factor Xa
Apixaban single dose	Apixaban single dose	Universitaire Ziekenhuizen KU Leuven	marketed	Direct Factor Xa inhibitor	Factor Xa
rivaroxaban (10mg)	rivaroxaban (10mg)	Chang Gung Memorial Hospital	marketed	Direct Factor Xa inhibitor	Factor Xa
Oroxid®	Oroxid®	Charles University, Czech Republic	marketed	Direct Factor Xa inhibitor	Factor Xa
Rivaroxaban or Marcumar	Rivaroxaban or Marcumar	RWTH Aachen University	marketed	Anticoagulant (Rivaroxaban: direct Factor Xa inhibitor; Marcumar: vitamin K antagonist)	Factor Xa (Rivaroxaban); Vitamin K epoxide reductase complex (Marcumar)
Rivaroxaban Oral Tablet	Rivaroxaban Oral Tablet	Swiss Paraplegic Research, Nottwil	marketed	Direct Factor Xa inhibitor	Factor Xa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2034-02-17 — Xarelto · 9539218 · Method of Use · US
2034-08-17 — Xarelto · 9539218*PED · Compound · US

Sponsor landscape (Direct Factor Xa Inhibitor class)

Johnson & Johnson · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xarelto — Competitive Intelligence Brief. https://druglandscape.com/ci/rivaroxaban. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab